The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.
News & Analysis: Codexis
The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.
CDXS earnings call for the period ending March 31, 2019.
Offset the rising cost of education with these three companies.
Investors with a long-term mind-set can look to these three stocks to inject growth into their portfolio.
These two companies saw their shares double in 2018. They're still buys for long-term investors.
The small biotech met 2018 guidance and expects another year of growth, but one segment's growth disappoints.
CDXS earnings call for the period ending December 31, 2018.
The enzyme leader announced a new and improved technology licensing deal with pharma giant Merck.
BlackBerry, Kinder Morgan, and Codexis could all have plenty of room to run.